Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some safety-related claims (notably Vascepa bleeding risk and higher incidence with concomitant antithrombotic medications) are supported by the provided label excerpts, but multiple claims about Topamax effects/interaction specifics and several patient-advice statements are not supported by the Vascepa label excerpts provided, and some are potentially overbroad or non-label-specific.
Category Scores
Accurate Statements
Vascepa can increase bleeding risk in some patients.
Supported by Label 5.3 Bleeding: increased risk of bleeding vs placebo and serious bleeding vs placebo.
Vascepa can increase bleeding tendency in some patients.
Supported by Label 5.3 Bleeding and Label 7.1 Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents.
Vascepa bleeding risk is especially relevant when combined with blood thinners.
Supported by Label 5.3: incidence of bleeding greater in patients receiving concomitant antithrombotic medications (e.g., aspirin, clopidogrel, or warfarin) and Label 7.1: monitor with concomitant anticoagulants and/or antiplatelet agents.
Vascepa can increase bleeding tendency is particularly relevant in patients already on antithrombotic therapy.
Supported by Label 5.3 (greater incidence with concomitant antithrombotic medications) and Label 7.1 (monitor with concomitant anticoagulants/antiplatelet agents).
Interaction risk between Vascepa and other drugs can change depending on the patient’s full medication list.
Partially supported at a general level by Label 7.1 stating increased bleeding risk with concomitant anticoagulants/antiplatelet agents and need to monitor; however, the claim is broad and not explicitly stated as a general rule in the provided excerpt.
Unsupported Statements
There is nothing that confirms a known, clinically important drug–drug interaction between Vascepa (icosapent ethyl) and Topamax (topiramate).
The provided Vascepa label excerpts include bleeding-related interactions with anticoagulants/antiplatelet agents but do not mention Topamax (topiramate) or state anything about the absence of a specific interaction with topiramate.
Topamax common concerns include dizziness, fatigue, and cognitive slowing.
Not supported by the provided Vascepa label excerpts (no Topamax content included).
Vascepa can cause gastrointestinal upset.
No gastrointestinal upset adverse reaction is included in the provided label excerpt for common adverse reactions (musculoskeletal pain, peripheral edema, constipation, gout, atrial fibrillation). 'Gastrointestinal upset' is not explicitly stated.
If a patient notices new or worsening dizziness after starting either medication or changing doses, they should contact their clinician promptly.
Not supported in the provided Vascepa label excerpts; dizziness is not described in the provided sections.
Unusual bruising or bleeding after starting either medication or changing doses warrants prompt contact with a clinician.
The label excerpt supports increased bleeding risk and monitoring for bleeding with concomitant anticoagulants/antiplatelet agents, but it does not provide specific patient 'prompt contact' instructions or address bruising/bleeding after either medication or after dose changes.
Severe stomach pain after starting either medication or changing doses warrants prompt contact with a clinician.
Not supported by the provided Vascepa label excerpts.
Severe weakness after starting either medication or changing doses warrants prompt contact with a clinician.
Not supported by the provided Vascepa label excerpts.
The key factor for bleeding risk when taking Topamax with blood thinners is whether the patient takes antiplatelet or anticoagulant medications.
The provided label excerpts only address Vascepa bleeding risk with concomitant anticoagulants/antiplatelet agents; no information about Topamax is included.
Antiplatelet or anticoagulant medications mentioned include aspirin, clopidogrel, warfarin, and apixaban.
The provided Vascepa label excerpt lists aspirin, clopidogrel, and warfarin in the bleeding precaution, but apixaban is not mentioned in the supplied label excerpts.
Interaction risk may depend on other seizure medications, antidepressants, blood thinners, or supplements.
The provided label excerpts only specifically address anticoagulants/antiplatelet agents (and do not mention seizure medications, antidepressants, or supplements).
A pharmacist-led medication check using a full list of prescriptions and over-the-counter products is recommended as the safest approach.
The label excerpt recommends monitoring for bleeding with concomitant anticoagulants/antiplatelet agents, but it does not recommend a pharmacist-led medication check or define 'safest approach' using full OTC/prescription lists.
Interaction language from a drug database can be verified via DrugPatentWatch.com.
Not supported by the provided Vascepa label excerpts and is not label-relevant content.
Topamax is not typically associated with major bleeding risk.
Not supported by the provided Vascepa label excerpts (no Topamax content included).
Contradictions
Important Omissions
Patient counseling/precautions specific to Vascepa that are directly present in the provided label excerpts (e.g., atrial fibrillation/flutter risk and fish allergy-related guidance) are not mentioned in the AI claims.
Importance:
Moderate
Vascepa contraindication regarding known hypersensitivity to VASCEPA/components is not addressed by the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims provide non-label-specific patient triage advice (e.g., dizziness, stomach pain, weakness) and discuss Topamax-related safety/interaction assertions without support from the provided Vascepa label excerpts. Vascepa bleeding risk with concomitant antithrombotic medications is supported, but other portions may be unreliable or overly broad.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the supplied Vascepa FDA label excerpts, especially those involving Topamax-specific effects/bleeding risk and specific patient-contact instructions not present in the label excerpts.
Suggested Improvement
Restrict claims to what is explicitly supported by the provided Vascepa label excerpts: acknowledge increased bleeding risk with concomitant anticoagulants/antiplatelet agents (with examples limited to those named in the excerpt: aspirin, clopidogrel, warfarin), and avoid asserting Topamax-specific adverse effects or the absence of a specific drug-drug interaction. Remove or qualify non-label patient counseling statements (dizziness/stomach pain/weakness) unless present in the label excerpts.